Properties
                                        
                            Description
                            Orelabrutinib is a compound designed to block Bruton’s tyrosine kinase (BTK), an enzyme essential for the proliferation and survival of certain cancerous B cells.
                         
                                                                            
                                                            
                            Molecular Formula
                            C26H25N3O3
                         
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
                                                            
                                                                                                                                                                                            
                            Identity
                            Confirmed by NMR/HPLC/MS.
                         
                                                                                                                                                            
                            Applications
                            Orelabrutinib is a BTK inhibitor, explored for its therapeutic potential in autoimmune conditions.